WASHINGTON (AP) -- Federal health advisers are endorsing an experimental vaccine to treat prostate cancer.
The Food and Drug Administration adviser voted unanimously to declare Provenge as safe. And in a 13-4 vote, the panel agreed to call it effective for treating advanced cases of prostate cancer that no longer respond to hormone treatment.
The F-D-A is not bound to follow the judgment of its advisory committees, but it usually does. A final F-D-A decision is expected in May.
If it is approved, Provenge would become the third cancer vaccine and the first for therapeutic use. Vaccines against liver and cervical cancer are both preventive.
Provenge in made by Seattle-based Dendreon Corporation.
Prostate cancer is the second most common cancer in American men, after skin cancer.